Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCrimson Tide Regulatory News (TIDE)

Share Price Information for Crimson Tide (TIDE)

Share Price is delayed by 15 minutes
Get Live Data
87.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 5.00 (5.882%)
Market Cap: £5.75m
TIDE Live PriceLast checked at - London Stock Exchange

Intraday Crimson Tide Share Chart

Customer Contracts Update

24 Dec 2025 07:00

RNS Number : 7312M
Crimson Tide PLC
24 December 2025
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION NO. 596/2014 (AS INCORPORATED INTO UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 AS AMENDED BY VIRTUE OF THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS 2019). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

24 December 2025

Crimson Tide plc

("Crimson Tide", the "Company" or the "Group")

Customer Contracts Update

Crimson Tide plc (AIM:TIDE), the provider of the mpro5 process management app, announces that it has received formal notice from a significant customer, a major retailer (the "Customer"), that it intends to exercise a break clause in its existing contract with the Company. The break clause will take effect on 31 March 2026. To note, this does not relate to the contract renewal which was announced on 10 November 2025.

The Company remains in constructive dialogue with the Customer regarding transition arrangements and is implementing mitigation strategies to reduce the impact of this change.

 

Whilst the Company is disappointed to lose a valued customer, this change will release considerable resources previously dedicated to servicing this account. The Customer's requirements necessitated significant bespoke development within the platform, which has constrained product development capacity. The conclusion of this contract will enable the Company to redeploy resources towards higher-margin opportunities, accelerate delivery of core product enhancements and support the Company's strategy to build a more scalable SaaS platform. Whilst there will be an immediate impact on revenue, the Board believes that this transition will benefit the Company over the longer term.

 

The contract, which commenced on 1 December 2024, represented approximately 12% of the Company's annual recurring revenue ("ARR") for the financial year ended 30 April 2025 and 30 April 2026, albeit at below average margins for the reasons explained above.

 

The Company has separately secured renewal agreements with two customers, representing combined monthly recurring revenue ("MRR") of approximately £14,700 for 12 months. Both customers had previously served notice of non-renewal and were therefore classified as churned. Following a renewed focus by the current management team on customer retention, and the implementation of a structured retention strategy focused on maximising customer value from mpro5, the Company has successfully re-engaged and retained both customers.

 

Enquiries:

 

Crimson Tide plc

+ 44 1892 542444

Chris Fielding, Non-Executive Chair

Jon Clarke, Chief Executive Officer

Rachael Rowe, Finance Director

Allenby Capital Limited - Nominated Adviser & Broker

+44 (0)20 3328 5656

Jeremy Porter / Ashur Joseph (Corporate Finance)

info@allenbycapital.com

Tony Quirke / Lauren Wright (Sales & Corporate Broking)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDPKNBNFBDDCBB
Date   Source Headline
4th Jan 20235:00 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector dealing
17th Nov 20227:00 amRNSSignificant contract expansion and extension
27th Sep 20227:00 amRNSInterim Results
25th Aug 20227:00 amRNSDirector Dealing
3rd Aug 20227:00 amRNSChange of Auditor
2nd Aug 20227:00 amRNSBoard Changes
25th Jul 20227:00 amRNSContract Win
19th Jul 20227:00 amRNSMultiyear contract win with major wholesaler
30th Jun 202211:27 amRNSResults of AGM & Statement
16th Jun 20224:30 pmRNSAnnual Report and Notice of AGM
7th Apr 20227:00 amRNSPreliminary Results
10th Feb 20227:00 amRNSContract Win and Strategic Partnership
3rd Feb 20227:00 amRNSTrading Update
7th Dec 20217:00 amRNSMaster Service Agreement with Compass Group
12th Nov 20217:00 amRNSDirectorate Change
11th Oct 202110:59 amRNSPDMR Dealing
28th Sep 20217:00 amRNSInterim Results
29th Jun 20213:08 pmRNSResult of AGM
16th Jun 20217:00 amRNSNorth America Appointment
4th Jun 20217:00 amRNSAnnual Report and Notice of AGM
4th May 20212:22 pmRNSTotal Voting Rights
28th Apr 202110:34 amRNSHolding(s) in Company
27th Apr 20217:00 amRNSHolding(s) in Company
26th Apr 20217:00 amRNSHolding(s) in Company
23rd Apr 20214:25 pmRNSHolding(s) in Company
23rd Apr 202110:37 amRNSPDMR Dealings
23rd Apr 202110:36 amRNSHolding(s) in Company
22nd Apr 202111:45 amRNSResult of General Meeting and Total Voting Rights
20th Apr 20217:00 amRNSContract Win
1st Apr 20213:52 pmRNSResult of Placing
1st Apr 202112:01 pmRNSPlacing to raise up to £6.0 million
1st Apr 202112:00 pmRNSPreliminary Results
18th Mar 20217:00 amRNSContract Win
1st Feb 20219:28 amRNSHolding(s) in Company
28th Jan 20217:00 amRNSAppointment of Director
26th Jan 20217:00 amRNSPilot with World Federation of Haemophilia
18th Jan 20219:36 amRNSHolding(s) in Company
12th Jan 20214:07 pmRNSHolding(s) in Company
7th Jan 20212:30 pmRNSHolding(s) in Company
23rd Dec 202012:15 pmRNSClarification re Grant of Options
22nd Dec 202010:45 amRNSGrant of Options under the Company's EMI Scheme
4th Dec 202011:35 amRNSHolding(s) in Company
17th Nov 20207:00 amRNSContract Wins
12th Nov 20204:27 pmRNSDirector/PDMR Shareholding
6th Nov 20201:15 pmRNSPDMR dealing
26th Oct 202010:08 amRNSHolding(s) in Company
5th Oct 20209:16 amRNSHolding(s) in Company
18th Sep 20207:00 amRNSInterim Results
14th Sep 20202:06 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.